Lucid Capital analyst Elemer Piros initiated coverage of Ocugen (OCGN) with a Buy rating and $15 price target Ocugen is developing next-generation, genetic medicines with the intention to save vision in genetic disorders of the eye, the analyst tells investors in a research note. The firm believes OCU400 in retinitis pigmentosa could see peak sales of $3.2B by 2032.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen Faces Merger Termination with Carisma Therapeutics
- Ocugen’s Strategic Advancements and Promising Prospects Justify Buy Rating
- Ocugen Signs Exclusive License Agreement with Kwangdong
- Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz
- Ocugen executes licensing agreement with Kwangdong Pharmaceutical